Polyoxidonium (azoximer bromide) 6 mg 5 vials

Instructions for Polyoxidonium (azoximer bromide) 6 mg 5 vials

Description

The solution for injection and local use is colorless or yellowish.

ATC Codes Polyoxidonium
L03 - Immunostimulators

Active substance Polyoxidonium
Azoximer bromide

Pharmacotherapeutic group
Immunomodulatory drugs

Pharmacological effect Polyoxidonium

Azoximer bromide is an immunomodulator that increases the body's resistance to local and systemic infections. Its mechanism of action is to directly affect phagocytic cells and natural killer cells and to stimulate antibody production.

Mode of application, course and dosage

Polyoxidonium® is used parenterally, intranasally, and sublingually.
The doctor determines the dosage, method of administration, and the need for subsequent courses of therapy based on the diagnosis, severity, and age of the patient.

Adults
IM or IV drip

The drug is given at a dose of six to twelve mg once a day, every other day, or once or twice a week, depending on the diagnosis and severity of the disease.

For acute viral and bacterial infections of the ENT organs, upper and lower respiratory tract, as well as gynecological and urological diseases, it is recommended to administer six mg of the drug daily for three days, then every other day in a course of ten injections.

For chronic recurrent infectious-inflammatory diseases of various localities caused by bacterial, viral or fungal infection, in the exacerbation phase, the drug is administered six mg every other day, a course consists of five injections, then two injections a week for ten injections.

For acute and chronic allergic diseases (pollinosis, bronchial asthma, atopic dermatitis), complicated by bacterial, viral or fungal infection, it is recommended to inject six to twelve mg of the drug, the course includes five injections.

For rheumatoid arthritis complicated by bacterial, viral, or fungal infection and long-term use of immunosuppressants, the drug is given six mg every other day for five injections, followed by two injections a week in a course of ten injections.

Indications Polyoxidonium

• For adults (as part of comprehensive treatment):
• Chronic infectious and inflammatory pathologies of a recurrent nature, provoked by bacteria, viruses or fungi.
• Acute infections of viral and bacterial nature involving ENT organs, respiratory system, genitourinary sphere and gynecological organs.
• Allergic conditions, such as pollinosis, asthma, and atopic dermatitis, can cause infectious complications.
• Cancer: prevention of immunosuppressive, nephrotoxic and hepatotoxic effects of drugs during chemotherapy and radiation therapy.
• Generalized infections in surgical practice
• Stimulation of tissue recovery in case of fractures, burns and trophic ulcers.
• Rheumatoid arthritis complicated by infections, especially if immunosuppressants are taken long-term.
• Pulmonary tuberculosis.
• For children older than 6 months (as part of complex therapy):
• Acute and chronic inflammatory processes of different localization,
• including ENT organs (sinusitis, rhinitis, adenoiditis, tonsillar hypertrophy) and ARVI.
• Acute allergic and toxico-allergic conditions with infectious complications.
• Asthma with respiratory tract infections.
• Atopic dermatitis complicated by purulent infection.
• Intestinal dysbacteriosis (in combination with other therapeutic methods).
• For prevention (monotherapy):
• Prevention of influenza and SARS in children over 6 months and adults.
• Prevention of infectious complications after surgery.

• Nosology Polyoxidonium (ICD codes)
• A15
• Tuberculosis of respiratory organs, confirmed by bacterial and histological culture
• A18
• Tuberculosis of other organs
• A56.0
• Lower genitourinary chlamydial infections
• A56.1
• Chlamydial infections of pelvic organs and other genitourinary organs
• A60
• Anogenital herpetic virus infection [herpes simplex]
• B00
• Herpes simplex virus infections [herpes simplex]
• D84.9
• Unspecified immunodeficiency
• H66
• Suppurative and unspecified otitis media
• J00
• Acute nasopharyngitis (runny nose)
• J01
• Acute sinusitis
• J02
• Acute pharyngitis
• J03
• Acute tonsillitis
• J04
• Acute laryngitis and tracheitis
• J06.9
• Acute upper respiratory tract infection, unspecified
• J10
• Influenza seasonal identified virus
• J30.1
• Allergic rhinitis due to plant pollen
• J31
• Chronic rhinitis, nasopharyngitis, and pharyngitis
• J32
• Chronic sinusitis
• J35
• Chronic diseases of tonsils and adenoids
• J35.0
• Chronic tonsillitis
• J37
• Chronic laryngitis and laryngotracheitis
• J45
• Asthma
• K63
• Other bowel diseases
• L20.8
• Other atopic dermatitis (neurodermatitis, eczema)
• L28.0
• Lichen simplex chronicus (limited neurodermatitis)
• L30.3
• Infective dermatitis (eczema infectiosum)
• L98.4
• Chronic skin ulcer, not elsewhere classified
• M05
• Seropositive rheumatoid arthritis
• N11
• Chronic tubulointerstitial nephritis (chronic pyelonephritis)
• N30
• Cystitis
• N34
• Urethritis and urethral syndrome
• N41
• Inflammatory diseases of the prostate
• N45
• Orchitis and epididymitis
• N70
• Salpingitis and oophoritis
• N71
• Inflammatory disease of uterus, except cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
• N72
• Inflammatory disease of cervix (incl. cervicitis, endocervicitis, exocervicitis)
• N76
• Other inflammatory diseases of vagina and vulva
• N89.8
• Other noninflammatory diseases of vagina
• T14.2
• Fracture of unspecified region of body
• T30
• Thermal and chemical burns of unspecified site
• Y43.1
• Anti-tumor antimetabolites
• Y43.2
• Anticancer natural drugs
• Y43.3
• Other antineoplastic drugs
• Y84.2
• Radiation procedure and radiation therapy
• Z29.8
• Other specified prophylaxis